Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Estradiol (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms MASTERS
- Sponsors BHR Pharma
- 06 Mar 2017 Status changed from recruiting to discontinued due to Inability to recruit patients.
- 20 Jul 2016 Planned End Date changed from 1 Oct 2017 to 1 Dec 2018.
- 20 Jul 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2017.